In a landmark regulatory decision, the U.S. Food and Drug Administration (FDA) has approved a new combination therapeutic regimen for the treatment of extensively drug-resistant tuberculosis (XDR-TB), offering hope to thousands of patients worldwide for whom existing treatments have failed.
Key Approval Details
The approval covers a 6-month all-oral regimen that demonstrated an 89% treatment success rate in Phase III clinical trials, compared to 52% for standard care. The therapy received Priority Review and Breakthrough Therapy Designation.
Global Impact & India Relevance
India bears the world’s highest TB burden, with over 2.8 million new cases annually. This approval is particularly significant as XDR-TB cases have been increasing in South Asian nations. CDSCO is expected to fast-track review of the submission for Indian approval.
Clinical Trial Data
- 89% treatment success rate at 6 months
- Reduced injection-based therapy requirement
- Favorable safety profile in 1,500+ patient trial
- Effective against both HIV-positive and HIV-negative patients
Pharmalix will continue to track the Indian regulatory pathway for this therapy. Subscribe to our regulatory alerts to stay updated.
Leave a Reply